Insider · CIK 0001823187
Andrew James King
Files at JBIO (Jade Biosciences, Inc.). First filing -, latest -.
Andrew James King files SEC Form 4 as officer at JBIO (Jade Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Andrew James King has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | JBIO Jade Biosciences, Inc. | AGrant or award Common Stock | +41,250 | $0.00 | $0 | 386,113 | Feb 13, 2026 |
| Feb 12, 2026 | JBIO Jade Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +247,500 | $0.00 | $0 | 247,500 | Feb 13, 2026 |
Questions about Andrew James King
Answered from the filings on this page, as of the latest one.
Is Andrew James King buying or selling?
Andrew James King has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Andrew James King's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Andrew James King has 0.
Where does Andrew James King file Form 4?
Andrew James King has filed Form 4 at JBIO (Jade Biosciences, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.